Artes Medical Inc. And BioForm Medical Announce Resolution Of All Outstanding Disputes And Litigation
SAN DIEGO and SAN MATEO, Calif., Nov. 1 /PRNewswire/ -- BioForm Medical, Inc., Artes Medical, Inc. and Dr. Martin Lemperle, one of Artes' founders, have resolved all of their outstanding disputes and litigation matters. According to the terms of the settlement, Artes has granted to BioForm an exclusive license under certain Artes patents to make and sell implant products containing Calcium Hydroxylapatite particles, including BioForm's Coaptite(R) and Radiesse(TM) products, and a non-exclusive license under the same patents to make and sell certain other non-polymeric implant products. BioForm has agreed to pay Artes a settlement amount plus past and future royalties.
About Artes Medical, Inc. and its product ArteFill(R)
Artes Medical, Inc. is a fully-integrated medical technology company focused on the development, manufacture and commercialization of a new category of injectable aesthetic products for the dermatology and plastic surgery markets. The Company's lead product candidate, ArteFill(R), is an injectable permanent micro-implant that has been shown to be safe and effective in U.S. clinical trials for the treatment of facial wrinkles known as smile lines, or nasolabial folds. ArteFill uses a propriety combination of Precision-Filtered Microspheres(TM) and Purified Bovine Collagen(TM) to stimulate the growth of a patient's natural collagen, which builds volume and provides enduring wrinkle correction. Artes refers to this novel mechanism of action as Aesthetic Tissue Engineering(TM). Based in San Diego, CA, Artes Medical was founded in 1999 and is privately-held. Additional information about the company is available at http://www.artesmedical.com .
About BioForm Medical, Inc. and its products Radiesse(TM) and Coaptite(R)
BioForm Medical, Inc. is a privately-held medical device company developing and commercializing injectable implant products for soft tissue augmentation. Radiesse(TM) and Coaptite(R) have an extensive record of safe clinical use in a variety of applications. Radiesse is marketed outside of the U.S. for facial soft tissue augmentation and vocal fold augmentation ("VFA") and is approved in the U.S. for VFA and maxillofacial augmentation. BioForm has recently completed two clinical trials evaluating Radiesse for nasolabial folds and facial lipoatrophy in the U.S., and has initiated the Pre-Market Approval ("PMA") process with the FDA for these indications. Coaptite is sold outside of the U.S. to treat female stress urinary incontinence ("SUI") and pediatric vesicoureteral reflux and is under PMA review for SUI in the U.S. For more information about BioForm, please visit the Company's website at www.bioformmedical.com.
Artes Medical, Inc. Contact: Stefan M. Lemperle, M.D. President & Chief Executive Officer Phone: 858-550-9999 BioForm Medical, Inc. Contact: Steven L. Basta President & Chief Executive Officer Phone: 650-286-4000
BioForm Medical, Inc.CONTACT: Stefan M. Lemperle, M.D., President & Chief Executive Officer ofArtes Medical, Inc., +1-858-550-9999; or Steven L. Basta, President & ChiefExecutive Officer of BioForm Medical, Inc., +1-650-286-4000